Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Crinetics Pharmaceuticals Inc (NQ: CRNX ) 42.19 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Crinetics Pharmaceuticals Inc < Previous 1 2 3 4 5 Next > 7 Biotech Stocks to Boost Your Portfolio to Peak Health June 26, 2024 With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. Via InvestorPlace EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner June 18, 2024 Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire 17 Analysts Have This To Say About Crinetics Pharmaceuticals June 04, 2024 Via Benzinga 18 Analysts Have This To Say About Crinetics Pharmaceuticals May 14, 2024 Via Benzinga The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts February 29, 2024 Via Benzinga Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday June 04, 2024 Via Benzinga Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS) June 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly June 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs May 30, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals: Q4 Earnings Insights February 28, 2024 Via Benzinga Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday May 22, 2024 Via Benzinga Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts May 22, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. Via InvestorPlace Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 May 08, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 May 02, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 11, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why March 19, 2024 Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy & safety, with plans for FDA submission in 2024. Via Benzinga Exposures Product Safety Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Leading the Way in Tuesday Trading Based on Percentage Gain March 19, 2024 Via Investor Brand Network National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday March 19, 2024 U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 19, 2024 Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. Via Benzinga Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win March 19, 2024 Biotech stock Crinetics Pharmaceuticals rocketed early Tuesday after solid trial results for its oral growth hormone treatment. Via Investor's Business Daily Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients March 19, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome March 12, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 11, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Via Benzinga Topics Stocks Exposures US Equities Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update February 28, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement February 28, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.